ArticleJournal of neuro-oncology2025
SIN1 facilitates glioma progression and is associated with the KRAS/ERK pathway.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeGlioma is the most common primary brain and spinal cord tumor, with effective treatments still lacking. Stress-activated protein kinase-interacting protein 1 (SIN1) has been reported to be upregulated in various tumor types, contributing to tumorigenesis. However, its specific role in glioma remains unclear. This study aimed to investigate SIN1's expression, clinical significance, biological functions, and underlying molecular mechanisms in glioma.
methodsSIN1 expression and its association with clinicopathological features and prognosis were analyzed using data from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA). SIN1 levels were quantified in glioma tissues and cell lines. The functional roles of SIN1 were evaluated by silencing or overexpressing it in glioma cells. RNA sequencing was used to identify downstream pathways, which were further validated through in vitro experiments. Additionally, the relationship between SIN1 and immune cell infiltration was investigated.
resultsSIN1 is aberrantly upregulated in glioma, significantly correlating with adverse clinicopathological features and poor patient prognosis. Functional studies reveal that SIN1 upregulation enhances glioma cell proliferation and migration while suppressing apoptosis. Mechanistically, SIN1 exerts its oncogenic effects might be through the KRAS4A/ERK pathway. Furthermore, SIN1 expression is associated with altered immune cell infiltration within the tumor microenvironment.
conclusionThis study identifies SIN1 as a critical oncoprotein in glioma, upregulated in tumors and associated with aggressive features and poor survival. It drives tumor progression by enhancing proliferation/migration and suppressing apoptosis might via the KRAS4A/ERK pathway, while potentially modulating immune infiltration. These findings highlight SIN1's promise as a novel therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.